Physician profile
Marium Khan
NPI 1962815852
$806.13
in general payments reported to CMS, 2019-2025
14 companies · $261 in 2025
The $261 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.82 · 2020: $11.86 · 2021: $16.80 · 2023: $250 · 2024: $190 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $701.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Steris Corporation | $157.66 | 2023 | |
| Lilly USA, LLC | $154.80 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $128.84 | 2025 | Ozempic, Wegovy, Saxenda |
| Pfizer INC. | $93.69 | 2019-2025 | |
| Exact Sciences Corporation | $64.31 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $43.03 | 2020-2025 | Prolia, Evenity |
| Tactile Systems Technology INC | $38.36 | 2024 | Entre Plus, Flexitouch Plus |
| Abiomed | $33.36 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $30.37 | 2023-2024 | Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $17.90 | 2023 | |
| Ibsa Pharma INC. | $17.32 | 2024 | Tirosint, Licart |
| Genentech, INC. | $14.86 | 2019 | |
| Boston Scientific Corporation | $11.63 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marium Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.